NEW YORK (GenomeWeb) – The National Cancer Institute's Office of Cancer Clinical Proteomics Research has announced it is seeking Tissue Source Sites.
These sites will prospectively collect primary human tumors according to a protocol optimized for proteomics for the NCI's Clinical Proteomic Tumor Analysis Consortium (CPTAC).
The CPTAC initiative has done protein biomarker discovery and verification studies in tumor tissue samples previously characterized at the genomic and transcriptomic level by the NCI's Cancer Genome Atlas (TCGA) team. In the first phase of the project, participating researchers undertook analysis of three tumor types — breast, colorectal, and ovarian.
In the next phase of the project the consortium aims to investigate "additional cancer types where questions remain unanswered on the complexity between the proteome and the genome in cancer," the NCI said, adding that this would require "acquisition of high-quality, clinically annotated, primary, and untreated tumor specimens."
Interested parties can learn more about the opportunity here.